TY - JOUR
T1 - Sceletium tortuosum (Zembrin®) ameliorates experimentally induced anxiety in healthy volunteers
AU - Reay, Jonathon
AU - Wetherell, Mark A.
AU - Morton, Emma
AU - Lillis, James
AU - Badmaev, Vladimir
N1 - © 2020 The Authors. Human Psychopharmacology: Clinical and Experimental published by John Wiley & Sons Ltd.
PY - 2020/8/6
Y1 - 2020/8/6
N2 - Objective: To investigate the anxiolytic properties of a standardized extract of Sceletium tortuosum (trademarked―Zembrin®). Methods: Two studies utilized a placebo-controlled, double-blind, between-subject experimental design to investigate the effects of a single dose of Sceletium tortuosum (25 mg, Zembrin®) on laboratory stress/anxiety responding in 20 young healthy volunteers. To elicit feelings of stress/anxiety, participants completed 20 min of the multitasking framework in study 1 and a 5-min simulated public speaking task in study 2. Study 1 measured subjective experiences of mood at baseline, prestress induction, and poststress induction. Study 2 measured subjective experiences of anxiety and physiological indicators of stress (heart rate [HR] and galvanic skin response) at baseline, prestress induction, during stress induction, and poststress induction. Results: A series of analysis of covariances (baseline entered as the covariate) revealed no treatment effect in study 1; however, study 2 revealed subjective anxiety levels to be significantly lower in the Zembrin® group at the prestress induction point and a significant interaction between treatment and time on HR. Taken together, results indicate that a single dose of Zembrin® can ameliorate laboratory stress/anxiety responding in healthy volunteers. Conclusion: We provide the first tentative behavioral evidence to support the anxiolytic properties of Sceletium tortuosum (25 mg Zembrin®).
AB - Objective: To investigate the anxiolytic properties of a standardized extract of Sceletium tortuosum (trademarked―Zembrin®). Methods: Two studies utilized a placebo-controlled, double-blind, between-subject experimental design to investigate the effects of a single dose of Sceletium tortuosum (25 mg, Zembrin®) on laboratory stress/anxiety responding in 20 young healthy volunteers. To elicit feelings of stress/anxiety, participants completed 20 min of the multitasking framework in study 1 and a 5-min simulated public speaking task in study 2. Study 1 measured subjective experiences of mood at baseline, prestress induction, and poststress induction. Study 2 measured subjective experiences of anxiety and physiological indicators of stress (heart rate [HR] and galvanic skin response) at baseline, prestress induction, during stress induction, and poststress induction. Results: A series of analysis of covariances (baseline entered as the covariate) revealed no treatment effect in study 1; however, study 2 revealed subjective anxiety levels to be significantly lower in the Zembrin® group at the prestress induction point and a significant interaction between treatment and time on HR. Taken together, results indicate that a single dose of Zembrin® can ameliorate laboratory stress/anxiety responding in healthy volunteers. Conclusion: We provide the first tentative behavioral evidence to support the anxiolytic properties of Sceletium tortuosum (25 mg Zembrin®).
UR - http://www.scopus.com/inward/record.url?scp=85089030523&partnerID=8YFLogxK
U2 - 10.1002/hup.2753
DO - 10.1002/hup.2753
M3 - Article
C2 - 32761980
AN - SCOPUS:85089030523
SN - 0885-6222
VL - 35
SP - 1
EP - 7
JO - Human Psychopharmacology
JF - Human Psychopharmacology
IS - 6
ER -